Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies
Carneiro, Benedito A, Cavalcante, Ludimila, Mahalingam, Devalingam, Saeed, Anwaar, Safran, Howard, Ma, Wen Wee, Coveler, Andrew L, Powell, Steven, Bastos, Bruno, Davis, Elizabeth, Sahai, Vaibhav, Mikrut, William, Longstreth, James, Smith, Sheri, Weisskittel, Taylor, Li, Hu, Borden, Brittany A, Harvey, R Donald, Sahebjam, Solmaz, Cervantes, Andrés, Koukol, Austin, Mazar, Andrew P, Steeghs, Neeltje, Kurzrock, Razelle, Giles, Francis J, Munster, Pamela
Published in Clinical cancer research (01.02.2024)
Published in Clinical cancer research (01.02.2024)
Get full text
Journal Article